Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-311-3 | CAS number: 57-09-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
An oral 28D study in rats has been conducted on a 24-26% cetrimonium chloride solution with dose-levels of 0; 30; 100; and 300 mg/kg bw/d (corresponding to 0; 7.5; 25, and 75 mg/kg bw/d). The dose was given as gavage in 10 ml of water/ kg bw. The NOAEL was 25 mg/kg bw/d. At 75 mg/kg bw/d severe local effects in the stomach was noted (thickening of forestomach mucosa, sporatic ilceration. Slight increase in adrenal weight and slight decrease in spleen weight were also noted at this dose level but this was only considered as possible and not clear systemic effects.
In an oral 1-year study rats were dosed via drinking water with cetrimonium bromide at 0; 10; 20 and 45 mg/kg bw/d. No histopathological findings were observed in the stomach (only organ subject to histopathological examination). At 45 mg/kg bw/d significant and persistent decrease in body weight was observed in male which was suggested to be due to lower observed efficiency of food conversion. The authors concluded that cetrimonium bromide may potentially prevent proper nutrition by increasing the rate of gastric emptying and intestinal transit and/or interfering with absorption of nutritional substances.
In an evaluation of the study by the SCCS, a NOAEL of 10 mg/kg bw/d from this study was concluded.
In a 28D dermal study with rabbits dosed on 25% of their body surface with 10 mg/kg bw/d ( 2 ml/kg bw/d) no systemic effects were noted.
However, the exposed skin showed mild to marked acanthosis with active mitosis, hyperkeratosis, and partial to extensive necrosis of the epidermis and hair follicles, partly with encrustation and exudate.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- chronic toxicity: oral
- Type of information:
- other: published study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: The published study is well described. The study was not performed according to GLP and no guideline was given.
- Reason / purpose for cross-reference:
- reference to other study
- Principles of method if other than guideline:
- No guideline is given.
- GLP compliance:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- 3-4 weeks old housed in groups of 5 animals with free access to food and water
- Route of administration:
- oral: drinking water
- Details on oral exposure:
- The rats were given CTAB in drinking water in concentrations calculated to deliver doses of approximately 10, 20, and 45 mg/kg/day. The concentrations of CTAB in drinking water were increased during the study so that the intake of test substance per bodyweight was approximately constant throughout the experimental period. When the animals attained maturity (6-7 weeks on test) the concentrations of CTAB in drinking water were 0.007, 0.014, and 0.032%.
- Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 56-60 weeks
- Frequency of treatment:
- Daily
- Remarks:
- Doses / Concentrations:
10, 20, 45 mg/kg/day
Basis:
nominal in water - No. of animals per sex per dose:
- 10
- Control animals:
- yes
- Details on study design:
- Animals were distributed in 4 experimental groups of 10 males and 10 females each, balanced with respect to body weights.
- Observations and examinations performed and frequency:
- The body weight, the length of the tail of each animal, and food and water consumption collectively for groups of 5 animals were recorded weekly during the first two months, biweekly during months 3 and 4 and monthly thereafter. Regular observations were made of the appearance and behavior of the animals.
- Sacrifice and pathology:
- The animals were killed 50-60 weeks after the beginning of the experiment. Blood was collected by heart puncture. Differential counts, haemoglobin determinations, quantitative determinations of serum protein, electrophoretic separation of serum proteins and determination of Na+ and K+ contents in serum were carried out. The liver, kidneys, heart, sleen, stomach, caecum, and submaxillary salivary glands were weighed. Specimens of the stomach and small intestine were fixed in buffered formalin, embedded in paraffin wax, and stained with Heidenhain's azan or kernechtrot.
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Wetting and discoloration of ventral fur of 50% of the animals in the 45 mg/kg/day dosage group
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Wetting and discoloration of ventral fur of 50% of the animals in the 45 mg/kg/day dosage group
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Reduced weight of the 45 mg/kg/day dosage group, males throughout the test period, females up to week 9 of the study
- Food efficiency:
- effects observed, treatment-related
- Description (incidence and severity):
- Decreased food efficiency of males in the 45 mg/kg/day dosage group up to week 8 of the study
- Haematological findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Reduced relative liver weight in males and increased relative caecum weight in both sexes in the 45 mg/kg/day dosage group. Increased relative caecum weight in males in the 20 mg/kg/day dosage group
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Reduced skeletal growth in the 45 mg/kg/day dosage group
- Dose descriptor:
- NOAEL
- Effect level:
- 10 mg/kg bw/day (nominal)
- Based on:
- act. ingr.
- Sex:
- male/female
- Basis for effect level:
- other: Clinical signs; body weight; food efficiency; haematology; gross pathology; organ weights; histopathology
- Critical effects observed:
- not specified
- Conclusions:
- Based on the results from the reported study it is concluded that cetrimonium bromide, when continuously administered in large doses, may potentially prevent proper nutrition by increasing the rate of gastric emptying and intestinal transit and/or by interfering with the absorption of nutritional substances. A NOAEL of 10 mg/kg/day is derived.
- Executive summary:
A publication from 1976 reports the adverse effects observed in groups of 10 male and 10 female Sprague Dawley rats when treated orally for one year with 10, 20 and 45 mg cetrimonium bromide/kg bw/day. The following effects were noted:
10 mg/kg bw/day: - no statistically significant effects were observed
20 mg/kg bw/day: - increased relative caecum weight in males
45 mg/kg bw/day: - significantly reduced mean body weights in both sexes after
3 weeks, persisting till end of study in males and for 9 weeks in
females
- males: significantly decreased efficiency of food conversion
- significantly reduced skeletal growth (judged by the growth of the
tail) in both sexes
- wetting and discoloration of ventral fur, often associated with a
brown discoloration of the fur
- males: reduced relative liver weight
- increased relative caecum weight in both sexes
No compound related changes were observed in haematological and clinical laboratory analyses of blood and urine. No gross necropsy changes were seen, and no microscopic alterations were found in the wall of stomach and small intestine of treated rats. No other tissues were subjected to histopathological examination.
Based on the results from the reported study it is concluded that cetrimonium bromide, when continuously administered in large doses, may potentially prevent proper nutrition by increasing the rate of gastric emptying and intestinal transit and/or by interfering with the absorption of nutritional substances. A NOAEL of 10 mg/kg/day is derived.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 10 mg/kg bw/day
- Study duration:
- chronic
- Species:
- rat
- Quality of whole database:
- Klimisch score 2. The systemic effects observed (reduced growth) is considered secondary to local effects in the gastrointestinal tract leading to decrease in feed efficiency of the animals.
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: dermal
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 1979
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Read-across to cetrimonium bromide from data on cetrimonium chloride (with data reliability value of 1). Read-across justifications are provided in the endpoint summary.
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 410 (Repeated Dose Dermal Toxicity: 21/28-Day Study)
- Deviations:
- yes
- Remarks:
- only one dose level used; dosing area 25% of body surface
- GLP compliance:
- not specified
- Limit test:
- yes
- Species:
- rabbit
- Strain:
- New Zealand White
- Sex:
- male/female
- Duration of treatment / exposure:
- 4 weeks
- Frequency of treatment:
- 6.5 to 7.0 h, 5 days a week
- Remarks:
- Doses / Concentrations:
10 mg/kg bw/d
Basis: - No. of animals per sex per dose:
- 5
- Control animals:
- yes
- Observations and examinations performed and frequency:
- observations for signs of toxicity and for mortality: twice a day
dermal irritation: scored daily
body weight: measured weekly
blood samples: taken prior to dosing and at week 4 for hematologic analyses
necropsy: either at the time of death or at the end of the study when they are killed - Clinical signs:
- no effects observed
- Description (incidence and severity):
- no death
- Dermal irritation:
- effects observed, treatment-related
- Description (incidence and severity):
- slight to moderate erythema
- Mortality:
- no mortality observed
- Description (incidence):
- no death
- Body weight and weight changes:
- no effects observed
- Haematological findings:
- no effects observed
- Details on results:
- Slight to moderate erythema was observed in all of the treated rabbits between days 4 and 8 but disappeared in four rabbits by day 17.
Very slight to slight edema was observed between days 6 and 12 in four rabbits and subsided by day 17.
Two rabbits had intermittent evidence of slight edema on day 20. No evidence of desquamation or coriaceousness was present in three rabbits. In the other rabbits, slight atonia was observed but persisted into week 4 in only three animals. Very slight to slight desquamation and coriaceousness was noted in most of the rabbits, but desquamation was found only in three animals and coriaceousness in two animals by week 4. Slight fissuring was observed in most of the rabbits but typically disappeared by the end of the study.
At necropsy, treatment-related changes were found only in the skin. The application sites of two rabbits were reddened, and one rabbit hadscabbing. Findings from microscopic examination included mild to marked acanthosis with active mitosis, hyperkeratosis, and partial to extensive necrosis of the epidermis and hair follicules with or without encrustation with exudate. No statistically significant changes were observed for the hepatic or renal weights between the experimental and control animals.
(The dose level of 10 mg/kg bw/d correspons to a dermal load of 0.05 mg/cm2 (assuming 25% of a body surface of 2500 cm2 (625 cm2) and a body weight of 3 kg) - Dose descriptor:
- LOAEL
- Remarks:
- dermal irritation
- Effect level:
- 10 mg/kg bw/day (nominal)
- Based on:
- dissolved
- Sex:
- male/female
- Basis for effect level:
- other: no systemic effects were noted
- Critical effects observed:
- not specified
- Conclusions:
- Although some treatment related changes were observed on the skin, they were mostly reversible. No deaths occurred in the experimental group, and no evidence of toxicity or hematological changes was present at the dose of 10 mg/kg bw/day.
- Executive summary:
Five New Zealand albino rabbits/sex/group were treated cutaneously with the test substance (cetrimonium chloride for 5 days/week for 4 weeks at a dose of 0 or 10 mg/kg bw/day (0 or 0.5% aqueous solutions, respectively). The dosage volume was 2.0 ml/kg bw with an approximate exposure period of 6.5 to 7 hours.
There were no treatment-related effects on body weight, haematology, organ weight, gross necropsy findings or histopathology, except for treated areas of the skin that showed mild to marked acanthosis with active mitosis, hyperkeratosis, and
partial to extensive necrosis of the epidermis and hair follicles, partly with encrustation and exudate.
(The dose level of 10 mg/kg bw/d correspons to a dermal load of 0.05 mg/cm2 (assuming 25% of a body surface of 2500 cm2 (625 cm2) and a body weight of 3 kg)
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 10 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rabbit
- Quality of whole database:
- Klimisch score 2
Repeated dose toxicity: dermal - local effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: dermal
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 1979
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Read-across to cetrimonium bromide from data on cetrimonium chloride (with data reliability value of 1). Read-across justifications are provided in the endpoint summary.
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 410 (Repeated Dose Dermal Toxicity: 21/28-Day Study)
- Deviations:
- yes
- Remarks:
- only one dose level used; dosing area 25% of body surface
- GLP compliance:
- not specified
- Limit test:
- yes
- Species:
- rabbit
- Strain:
- New Zealand White
- Sex:
- male/female
- Duration of treatment / exposure:
- 4 weeks
- Frequency of treatment:
- 6.5 to 7.0 h, 5 days a week
- Remarks:
- Doses / Concentrations:
10 mg/kg bw/d
Basis: - No. of animals per sex per dose:
- 5
- Control animals:
- yes
- Observations and examinations performed and frequency:
- observations for signs of toxicity and for mortality: twice a day
dermal irritation: scored daily
body weight: measured weekly
blood samples: taken prior to dosing and at week 4 for hematologic analyses
necropsy: either at the time of death or at the end of the study when they are killed - Clinical signs:
- no effects observed
- Description (incidence and severity):
- no death
- Dermal irritation:
- effects observed, treatment-related
- Description (incidence and severity):
- slight to moderate erythema
- Mortality:
- no mortality observed
- Description (incidence):
- no death
- Body weight and weight changes:
- no effects observed
- Haematological findings:
- no effects observed
- Details on results:
- Slight to moderate erythema was observed in all of the treated rabbits between days 4 and 8 but disappeared in four rabbits by day 17.
Very slight to slight edema was observed between days 6 and 12 in four rabbits and subsided by day 17.
Two rabbits had intermittent evidence of slight edema on day 20. No evidence of desquamation or coriaceousness was present in three rabbits. In the other rabbits, slight atonia was observed but persisted into week 4 in only three animals. Very slight to slight desquamation and coriaceousness was noted in most of the rabbits, but desquamation was found only in three animals and coriaceousness in two animals by week 4. Slight fissuring was observed in most of the rabbits but typically disappeared by the end of the study.
At necropsy, treatment-related changes were found only in the skin. The application sites of two rabbits were reddened, and one rabbit hadscabbing. Findings from microscopic examination included mild to marked acanthosis with active mitosis, hyperkeratosis, and partial to extensive necrosis of the epidermis and hair follicules with or without encrustation with exudate. No statistically significant changes were observed for the hepatic or renal weights between the experimental and control animals.
(The dose level of 10 mg/kg bw/d correspons to a dermal load of 0.05 mg/cm2 (assuming 25% of a body surface of 2500 cm2 (625 cm2) and a body weight of 3 kg) - Dose descriptor:
- LOAEL
- Remarks:
- dermal irritation
- Effect level:
- 10 mg/kg bw/day (nominal)
- Based on:
- dissolved
- Sex:
- male/female
- Basis for effect level:
- other: no systemic effects were noted
- Critical effects observed:
- not specified
- Conclusions:
- Although some treatment related changes were observed on the skin, they were mostly reversible. No deaths occurred in the experimental group, and no evidence of toxicity or hematological changes was present at the dose of 10 mg/kg bw/day.
- Executive summary:
Five New Zealand albino rabbits/sex/group were treated cutaneously with the test substance (cetrimonium chloride for 5 days/week for 4 weeks at a dose of 0 or 10 mg/kg bw/day (0 or 0.5% aqueous solutions, respectively). The dosage volume was 2.0 ml/kg bw with an approximate exposure period of 6.5 to 7 hours.
There were no treatment-related effects on body weight, haematology, organ weight, gross necropsy findings or histopathology, except for treated areas of the skin that showed mild to marked acanthosis with active mitosis, hyperkeratosis, and
partial to extensive necrosis of the epidermis and hair follicles, partly with encrustation and exudate.
(The dose level of 10 mg/kg bw/d correspons to a dermal load of 0.05 mg/cm2 (assuming 25% of a body surface of 2500 cm2 (625 cm2) and a body weight of 3 kg)
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LOAEL
- 0.05 mg/cm²
- Study duration:
- subacute
- Species:
- rabbit
Additional information
No clear systemic effects have been observed in the repeated dose toxicity studies with cetrimonium chloride and cetrimonium bromide.
The local effects are considered the most critical effects in connection with repeated exposure.
The lack of systemic effects in the repeated dose toxicity studies may be explained by a low dermal and oral absorption rates as indicated by the toxicokinetic studies where absorption rates for dermal and oral exposure have been estimated to 3% and 6%, respectively.
As seen from the repeated dose toxicity studies the potent local effect of the substance very much limit the exposure levels to be used in repeated dose toxicity studies for further examining systemic effects. Thus there seems to be no rationale for further testing of cetrimonium bromide at ANNEX IX level.
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
The only available RDT study on cetrimonium bromide (1 year study).
Justification for selection of repeated dose toxicity dermal - systemic effects endpoint:
28D repeated dermal toxicity study on cetrimonium chloride for read-across to cetrimonium bromide
Justification for selection of repeated dose toxicity dermal - local effects endpoint:
28D repeated dermal toxicity study on cetrimonium chloride for read-across to cetrimonium bromide
Repeated dose toxicity: via oral route - systemic effects (target organ) digestive: other
Justification for classification or non-classification
Using read-across to the 28D oral study on cetrimonium chloride where severe effects were noted in the gastrointestinal tract at a dose level of 75 mg/kg bw/d the substance (cetrimonium bromide) should according to the CLP regulation be classified as STOT RE 2; H373 (oral route; gastrointestinal tract)
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

Route: .live1